Clasificación en acciones
#21916
ABIONYX Pharma SA is a biotechnology company dedicated to the identification... ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This compound is designed to mimic the structural and functional attributes of pre-beta HDL, utilizing human recombinant apoA-I (a natural high-density lipoprotein protein) along with natural phospholipids like sphingomyelin and dipalmitoylphosphatidylglycerol. CER-001 is currently under development for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Another key candidate, CER-002, is a specific agonist for peroxisome proliferator-activated receptor delta, targeting cardiovascular and metabolic diseases. Additionally, CER-209 is being developed as a potential treatment for metabolic liver diseases, atherosclerosis, and non-alcoholic steatohepatitis (NASH). ABIONYX maintains strategic partnerships with GTP Biologics and VBI Therapeutics Group for the bioproduction of its bio-HDL in France. Established in 2005, the company operated as Cerenis Therapeutics Holding SA before its rebranding to ABIONYX Pharma SA in August 2019. Its operations are headquartered in Balma, France.
Precio por acción
$2.32
Última sincronización: 2026-08-21
Capitalización bursátil
$98.03M
Comercio ABIONYX Pharma S.A. (ABNX)
Precio ABNX con Capital del mercado a B
Capitalización de mercado de ABIONYX Pharma S.A.(ABNX)
Capitalización bursátil: $98.03M
A fecha de August 2026, ABIONYX Pharma S.A. tiene una capitalización de mercado de $98.03M. Esto convierte a ABIONYX Pharma S.A. en la 21916th empresa más valiosa del mundo por capitalización bursátil, según nuestros datos. La capitalización bursátil es el valor total de mercado de las acciones en circulación de una empresa que cotiza en bolsa y se utiliza comúnmente para medir su valor.
Historial de capitalización de mercado de ABIONYX Pharma S.A. desde 2015 hasta 2026
ABNX en comparación con los más populares 5 títulos stocks
| Precio por ABNX |
|
Activo B |
Capital del mercado en B |
Resultados |
|
|
|
|
$5.211T
|
+5,316,238.88%
|
|
|
|
|
$4.547T
|
+4,638,228.81%
|
|
|
|
|
$4.162T
|
+4,246,218.63%
|
|
|
|
|
$3.593T
|
+3,665,058.50%
|
|
|
|
|
$2.793T
|
+2,849,009.38%
|
